LYNO AI Reports Strong Momentum in Early Bird Presale Ahead of Price Increase to $0.055
ROAD TOWN, British Virgin Islands, Aug. 13, 2025 (GLOBE NEWSWIRE) — LYNO AI is progressing at a rapid pace during its Early Bird presale period, attracting attention from traders and investors. The project's autonomous AI-powered cross-chain arbitrage engine operates across more than 15 EVM-compatible blockchains, contributing to the growing participation in the presale.
At this stage, LYNO tokens are priced at $0.050 per token, with a total of 16 million tokens available. More than 265,000 tokens have already been sold, reflecting heightened interest ahead of the upcoming price adjustment to $0.055 per token.
Presale Details Highlight Limited-Time Opportunity
The Early Bird stage provides participants with the chance to acquire LYNO tokens at the current rate before the planned increase. Key presale data include: Current token price: $0.050
Next stage token price: $0.055
Tokens sold so far: 265,879.247
Total tokens allocated: 16 million
Payments can be made via ETH, USDT, or USDC, using supported wallets such as MetaMask and Trust Wallet.
Additionally, buyers who purchase more than $100 in LYNO tokens will be entered into the LYNO AI Giveaway for a chance to win one of ten 10,000-token prizes from a 100,000-token pool.
Technology Designed for Cross-Chain Arbitrage
LYNO AI is an open-source, decentralized protocol that applies advanced machine learning to identify and execute arbitrage opportunities across blockchain networks, including Ethereum, BNB Chain, Polygon, Arbitrum, and Optimism. Its automated system incorporates: Real-time market data aggregation
AI-driven scoring and routing of profitable arbitrage opportunities
Automated trade execution using flash loans and cross-chain bridges
Continuous profit distribution and AI model updates
Holders of the $LYNO token have governance rights, enabling participation in protocol-related decisions. Staking options are available, with up to 60 percent of protocol fees distributed to the community. The system includes a buyback and burn mechanism to help manage token supply.
Security measures include multi-signature wallets, slippage controls, and zero-knowledge proofs to help prevent front-running and MEV attacks. The protocol has been audited by Cyberscope.
Early Participation Encouraged Before Price Change
With the Early Bird stage advancing toward its allocation limit, participants have a short window to secure tokens at $0.050 before the next pricing level of $0.055. This presale period offers early access to a decentralized finance protocol integrating AI technology with cross-chain arbitrage capabilities.
Additional Information
Website: https://lyno.ai/Buy Presale: https://lyno.ai/#presaleWhitepaper: https://lyno.ai/whitepaper.pdfTwitter/X: https://x.com/Lyno_AITelegram: https://t.me/lyno_ai
Win 100k: https://gleam.io/KCCV3/lyno-ai-giveaway
Contact DetailsLYNO AI
[email protected]
Disclaimer: This content is provided by LYNO AI. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice.Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed.Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.
Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/d487b4c8-bb8c-4f15-9a75-7bd3058dd05b
https://www.globenewswire.com/NewsRoom/AttachmentNg/49026c2b-2e03-48a5-95d8-cd9425e2feb6
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Edible Garden Delivers Strong Performance Across Core and Key Segments, Driven by Strategic Portfolio Transformation
Company exits low-margin product lines, invests in higher-margin, innovative CEA-informed, better-for-you shelf-stable products, and expands global reach Conference Call to Be Held Today at 8:00 am ET. BELVIDERE, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated ('Edible Garden' or the 'Company') (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, better-for-you, sustainable produce and products, today reported strong core business performance for the three months ended June 30, 2025, and shared a strategic business update. This performance reflects the Company's disciplined portfolio optimization strategy following a recent acquisition, which involved eliminating underperforming, low-margin product lines and making targeted investments in higher-margin, innovative, CEA-informed, better-for-you consumer packaged goods. These strategic initiatives position the Company to strengthen its leadership in shelf-stable, wellness-focused products that align with growing consumer demand for quality, functionality, and sustainability. Financial & Operating Highlights for the Three Months Ended June 30, 2025 Non-perishable unit sales increased approximately 17% year-over-year, driven by strong performance across the Company's shelf-stable product lines including Kick. Sports Nutrition, Pickle Party™, Pulp®, and Vitamin Whey®. Private Label products sold through major big box retailers outperformed in the second quarter, climbing 19.1% year-over-year Hydroponic Basil up 7.1%, Potted Herbs up 6.4%, and Wheatgrass up 4.1% International vitamin and supplements revenue rose 66.5% versus year-over-year 'Our results this quarter validate the disciplined choices we've made to focus on higher-margin, innovation-driven categories that align with where the market is headed,' said Jim Kras, Chief Executive Officer of Edible Garden. 'By exiting underperforming, low-margin product lines and investing in CEA-informed, better-for-you shelf-stable products, we are building a stronger, more resilient portfolio. We believe this strategy will not only drive profitability but also position us to lead in delivering sustainable, wellness-oriented solutions to consumers worldwide.' "Private Label products sold through major big box retailers outperformed in the second quarter, climbing 19.1% year-over-year, driven by expanded programs and strong sell-through of our sustainably grown, CEA-produced herbs. This momentum carried into our produce category, led by Hydroponic Basil up 7.1%, Potted Herbs up 6.4%, and Wheatgrass up 4.1%. We also advanced our strategic priorities in innovation, brand expansion, and operational sustainability with the launch of Kick Sports Nutrition on Amazon, continued retail growth of Pickle Party™, and the debut of the industry's first USDA Certified Organic Hydroponic Basil. Together with strong gains in our non-perishable lines, these achievements further diversify our portfolio and reinforce Edible Garden's leadership in controlled environment agriculture. In addition, international vitamin and supplements revenue rose 66.5% as we forged new distribution partnerships and expanded retail placements in key markets." 'We also strengthened our operational capabilities this quarter with the acquisition of the NaturalShrimp aquaculture facility in Iowa, now operating as Edible Garden Prairie Hills. This addition enhances our R&D in aquaponics, brings patented water treatment technologies into our IP portfolio, improves distribution efficiency potential from its central Midwest location, and provides the capacity to scale future production and launch new product lines—all of which will position us for greater innovation, efficiency, and long-term growth.' "In the second quarter, we advanced our strategic priorities across innovation, brand expansion, and operational sustainability, delivering strong performance in both our non-perishable and fresh produce categories. This category posted unit growth, fueled by the launch of our Kick Sports Nutrition line on Amazon, which expanded our digital marketing reach, drove higher direct-to-consumer engagement, and contributed to a surge in e-commerce sales." Demand for better-for-you CPG products is rising, with the global functional food and beverage market expected to grow from $400 billion to $610 billion by 2030 (Virtue Market Research). In the U.S., natural, organic, and functional product sales are projected to reach $386 billion by 2028, growing about 5% annually (Nutrition Business Journal). The Company believes that its differentiated brand portfolio is well-positioned to benefit from these long-term was $3.1 million for the three months ended June 30, 2025, compared to $4.3 million in the second quarter of 2024. The decrease was primarily due to the Company's strategic exit from the floral and lettuce categories, which contributed $741,000 to the decline. While the Company has not yet fully offset the lost revenue from floral, that category had high costs and low returns and did not align with the Company's better-margin strategy. Gross profit totaled $634,000, compared to $1.56 million in Q2 2024. The year-over-year change reflects shifts in product mix and sales volume, along with higher labor and raw material costs. Non-perishable revenue increased approximately 15% year-over-year, driven by strong performance across the Company's shelf-stable product lines including Kick. Sports Nutrition, Pickle Party™, Pulp®, and Vitamin Whey®. Margin pressure was also influenced by continued investment in infrastructure and personnel needed to support the Company's transition and future scalability. Selling, general and administrative expenses ('SG&A') totaled $4.2 million for the three months ended June 30, 2025, compared to $2.7 million in the prior-year period. The year-over-year increase was primarily driven by legal costs related to the NaturalShrimp asset acquisition, expenses associated with the Narayan transaction, and franchise tax charges. Net loss was $4.0 million for the three months ended June 30, 2025, compared to a net loss of $1.9 million for the three months ended June 30, 2024. The year-over-year increase in net loss was primarily driven by higher SG&A expenses related to strategic transactions and a decline in revenue from the planned exit of low-margin product categories. The complete financial results for the quarter ended June 30, 2025, are available in the Company's Quarterly Report on Form 10-Q, which will be filed with the Securities and Exchange Commission and available at: Conference Call Edible Garden will host a conference call today at 8:00 A.M. Eastern Time to discuss the Company's financial results for the quarter ended June 30, 2025, as well as the Company's corporate progress and other developments. The conference call will be available via telephone by dialing toll-free +1 877-545-0523 for U.S. callers or +1 973-528-0016 for international callers and entering access code 639542. A webcast of the call may be accessed at or on the investor relations section of the Company's website, A webcast replay will be available on the investor relations section of the Company's website at through August 14, 2026. A telephone replay of the call will be available approximately one hour following the call, through August 28, 2025, and can be accessed by dialing +1 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 52816. ABOUT EDIBLE GARDEN® Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering locally grown, organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired® next-generation farming model. Available in over 5,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. Edible Garden's proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1). The Company has been recognized as a FoodTech 500 firm by Forward Fooding, a leading AgriFoodTech organization, and is a Giga Guru member of Walmart's Project Gigaton sustainability initiative. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way® and Vitamin Whey®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company's offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts. Learn more at For Pulp products, visit For Vitamin Whey® products, visit For Kick. Sports Nutrition products, visit Watch the Company's latest corporate video here. Forward-Looking Statements This press release contains forward-looking statements, including with respect to the Company's ability to improve its financial results, the Company's growth strategies, the Company's ability to expand into new product lines, and its performance as a public company. The words 'believe,' 'design,' 'expect,' 'future,' 'potential,' 'will,' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including market and other conditions and the Company's ability to improve its financial performance and achieve its growth objectives, and other factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's annual report on Form 10-K for the year ended December 31, 2024 and subsequent quarterly reports on Form 10-Q. Actual results might differ materially from those explicit or implicit in the forward-looking statements. The Company undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations, except as required by law. Investor Contacts:Crescendo Communications, LLC212-671-1020EDBL@ (tables follow) EDIBLE GARDEN AG INCORPORATED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except shares) June 30, December 31, 2025 2024 ASSETS Current assets: Cash $ 2,821 $ 3,530 Accounts receivable, net 1,211 1,968 Inventory, net 1,367 1,544 Prepaid expenses and other current assets 490 335 Total current assets 5,889 7,377 Property, equipment and leasehold improvements, net 11,006 3,145 Operating lease right-of-use assets 4,480 1,202 Finance lease right-of-use assets 92 114 Intangible assets, net 313 43 Other assets 34 34 TOTAL ASSETS $ 21,814 $ 11,915 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) LIABILITIES: Current liabilities: Accounts payable and other accrued expenses $ 2,375 $ 4,018 Current maturities of operating lease liabilities 219 212 Current maturities of finance lease liabilities 43 41 Short-term debt, net of discounts 1,317 1,939 Total current liabilities 3,954 6,210 Long-term liabilities: Long-term debt, net of discounts 334 544 Long-term operating lease liabilities 881 992 Long-term finance lease liabilities 53 75 Total long-term liabilities 1,268 1,611 Total liabilities 5,222 7,821 COMMITMENTS AND CONTINGENCIES MEZZANINE EQUITY Series B redeemable preferred stock 15,000 - STOCKHOLDERS' EQUITY (DEFICIT): Common stock ($0.0001 par value, 100,000,000 shares authorized, 2,828,661 and 1,065,402 shares outstanding as of June 30, 2025 and December 31, 2024, respectively - - Preferred stock - - Additional paid-in capital 50,270 44,946 Obligation to issue shares - 459 Accumulated deficit (48,678 ) (41,311 ) Total stockholders' equity (deficit) 1,592 4,094 TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT) $ 21,814 $ 11,915 EDIBLE GARDEN AG INCORPORATED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per-share information) Three Months Ended June 30 Six Months Ended June 30 2025 2024 2025 2024 Revenue $ 3,146 $ 4,268 $ 5,864 $ 7,401 Cost of goods sold 2,512 2,702 5,142 5,811 Gross profit 634 1,566 722 1,590 Selling, general and administrative expenses 4,227 2,748 7,242 6,632 Gain on sale of asset - - (1 ) - Loss from operations (3,593 ) (1,182 ) (6,519 ) (5,042 ) Other income (expenses) Interest expense, net (389 ) (419 ) (829 ) (536 ) Gain (Loss) from extinguishment of debt (114 ) (335 ) (114 ) (335 ) Other income / (loss) 53 4 95 4 Total other income (expenses) (450 ) (750 ) (848 ) (867 ) NET LOSS $ (4,043 ) $ (1,932 ) $ (7,367 ) $ (5,909 ) Deemed dividend on warrants (9,833 ) - (9,833 ) - NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (13,876 ) $ (1,932 ) $ (17,200 ) $ (5,909 ) Net Income / (Loss) per common share - basic and diluted $ (6.58 ) $ (30.02 ) $ (9.95 ) $ (155.46 ) Weighted-Average Number of Common Shares Outstanding – Basic and Diluted 2,109,267 64,361 1,728,414 38,009 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
32 minutes ago
- Business Insider
QF Network Confirms Q4 2025 Mainnet Launch to Redefine Layer-1 Blockchain Performance
QF Network (QF) today confirmed that its mainnet will go live in Q4 2025, entering the market with performance and architecture designed to reshape what is possible for Layer-1 blockchains. While Ethereum co-founder Vitalik Buterin recently floated the idea of moving the Ethereum Virtual Machine (EVM) to a RISC-V architecture, QF has already built its core around this new technology. The result is a network that is faster, more efficient, and built for mass adoption from day one. Designed to safeguard what it calls the five pillars of digital life, which are identity, money, work, community, and data, QF Network achieves block times of just 0.1 seconds through its SPIN consensus without compromising decentralization, a feat no other Layer 1 has achieved. This architecture delivers throughput up to 10× higher than standard Substrate chains and is engineered to support millions of daily users without performance bottlenecks, thanks to its parallel execution engine. 'Our mainnet launch is not just about going live, it is about proving that a blockchain can be fast, scalable, and still sovereign by design,' said Ben Burge, Founder of Quantum Fusion Network. 'We have built the foundation for dApps that feel instant, secure, and unstoppable.' QF's native-first SDK, verifiable off-chain compute, and zkTLS integration create an environment where developers can build applications that match Web2 performance without compromising decentralization. This technical stack bridges Web2 and Web3, maintaining security and verification while removing friction for end users. For developers, this means the ability to compete with centralized platforms on speed and reliability while retaining core blockchain principles. For users, it means experiencing decentralized applications without the latency, throughput limits, or usability compromises that have slowed blockchain adoption. Mainnet is on track for Q4 2025. When it arrives, QF intends not just to join the Layer-1 race, but to set a new standard for it. About QF Network QF Network is a sovereign Layer-1 blockchain built to safeguard identity, money, work, community, and data for the next century. Powered by SPIN consensus, parallel execution, RISC-V architecture, verifiable off-chain compute, and zkTLS, QF delivers Web2-grade performance without sacrificing neutrality or decentralization. Contact Co Founder Ben Burge QF Network
Yahoo
40 minutes ago
- Yahoo
Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026 Top-line results for Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations remain on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations Company plans to announce both a third clinical indication for QTORIN™ rapamycin and a second QTORIN™ platform candidate before year-end 2025 Cash and cash equivalents of $70.4 million as of June 30, 2025 are expected to fund operations into the second half of 2027 Company to host conference call at 8:30 a.m. ET today WAYNE, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or 'the Company'), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, reported financial results for the second quarter ending June 30, 2025 and provided a corporate update. 'In the second quarter of 2025, we continued to advance Palvella's mission of pioneering first-in-disease therapies for individuals with serious, rare genetic skin diseases,' said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. 'We remain on track for two near-term data readouts for QTORIN™ rapamycin, including our Phase 3 SELVA study in microcystic LMs which we believe will support a New Drug Application submission in 2026. In parallel, we are preparing to announce two new development programs in 2025, further expanding our rare disease pipeline. With strong momentum and a solid financial foundation, Palvella is well-positioned for continued growth and execution on our vision.' Recent Research and Development Highlights QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) Completed enrollment in the Phase 3 SELVA trial, a single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin for the treatment of microcystic LMs; trial enrolled 51 subjects, exceeding its original target of 40 subjects by over 25%. The Company received initial proceeds from an FDA Orphan Products Grant which could total up to $2.6 million to support the Phase 3 SELVA trial. The FDA Orphan Products Grants Program provides non-dilutive funding to advance the development of promising therapies for rare diseases. Key presentations and posters featured at major scientific meetings included: Oral presentation highlighting QTORIN™ rapamycin for the treatment of microcystic LMs was presented by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology; the presentation highlighted the Phase 3 SELVA trial design and reviewed Phase 2 results. Poster highlighting the estimated diagnosed U.S. prevalence and U.S. annual incidence of lymphatic malformations was presented at the 82nd Annual Meeting of the Society for Investigative Dermatology. The United States Patent and Trademark Office (USPTO) issued patent No. 12,268,673 with claims to QTORIN™ rapamycin for the treatment of microcystic LMs with anticipated patent life extending into 2038. Top-line results from SELVA are on track for the first quarter of 2026. QTORIN™ rapamycin for the treatment of cutaneous venous malformations (cutaneous VMs) Continued execution of ongoing Phase 2 TOIVA trial, a single-arm, open-label, baseline-controlled clinical trial evaluating QTORIN™ rapamycin for the treatment of cutaneous VMs. Enrollment is ongoing, targeting approximately 15 subjects. The Company, in collaboration with key opinion leaders in treating venous malformations, completed a nationally representative, blinded, real-world observational study estimating the U.S. annual prevalence of cutaneous VMs, with findings submitted to a peer reviewed journal. Top-line results from TOIVA are on track for the fourth quarter of 2025. QTORIN™ pipeline development The expansion of QTORIN™ rapamycin into a third serious, rare skin disease with no FDA-approved therapies is progressing, with clinical and regulatory planning ongoing, and announcement of the program is planned for the second half of 2025. The second product candidate from the QTORIN™ platform for a serious, rare skin disease with no FDA-approved therapies, has achieved key pre-clinical development milestones, and announcement of the program is planned for the second half of 2025. Recent Corporate Highlights Wes Kaupinen, Palvella's Founder and CEO, participated in the FDA's CEO Forum with Commissioner Marty A. Makary, M.D., M.P.H, and other senior FDA officials on June 5th. Strengthened executive leadership team with the appointment of Ashley Kline, a rare disease commercial veteran, as Chief Commercial Officer. Ashley previously led the successful launch of Oxervate®, a first-in-disease topical therapy for neurotrophic keratitis, a rare, serious, and progressive eye disease that previously had no FDA-approved therapies. The USPTO issued patent No. 12,329,748 encompassing a wide range of composition and method-of-use claims for QTORIN™ rapamycin and other mTOR inhibitors formulated in 0.1–20% anhydrous compositions for a broad spectrum of rare and common skin diseases, with patent term expected through at least 2038. The Company was added to the Russell 3000® and Russell 2000® indexes on June 27, 2025. Second Quarter 2025 Financial Results Cash and cash equivalents as of June 30, 2025 were $70.4 million. Palvella expects such resources will be sufficient to fund its operations into the second half of 2027, and sufficient to accomplish its current strategic agenda. Research and development expenses were $5.1 million for the three months ended June 30, 2025, as compared to $1.4 million for the three months ended June 30, 2024. The increase in research and development expenses was primarily due to increased spending on the clinical development of QTORIN™ rapamycin for the treatment of microcystic LMs and cutaneous VMs, including conducting the Phase 3 SELVA and Phase 2 TOIVA trials, which were initiated in 2H 2024. General and administrative expenses were $4.1 million for the three months ended June 30, 2025, as compared to $1.5 million for the three months ended June 30, 2024. The increase in general and administrative expenses was primarily driven by increased employee compensation expense due to headcount additions, as well as increases in expenses related to operating as a publicly-traded company. Net loss attributable to common stockholders was $9.5 million, or $0.86 per basic and diluted share, for the three months ended June 30, 2025, as compared to net loss attributable to common stockholders of $4.4 million, or $2.47 per basic and diluted share, for the three months ended June 30, 2024. Shares outstanding were 13,735,390 as of August 8, 2025, including 11,059,665 shares of common stock and 2,675,725 common share equivalents assuming conversion of outstanding preferred shares and prefunded warrants. Conference Call Details Palvella will host a conference call and live audiovisual webcast to discuss the Company's second quarter 2025 financial results and provide a corporate update at 8:30 a.m. ET today. To access the live webcast of the call with slides, please click here or visit the 'Events & Presentations' section of Palvella's website. To access the call by phone, please use this registration link, and you will be provided with dial in details. A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the 'Events & Presentations' section of the Company's website at About Palvella Therapeutics Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication. Forward-Looking Statements This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from ongoing clinical trials, Palvella's clinical development plans and related anticipated development milestones, Palvella's cash and financial resources and expected cash runway, and the potential of, and expectations regarding, Palvella's programs, including QTORIN™ rapamycin, and its research-stage opportunities and any additional indications or platform candidates, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella's product candidates, including QTORIN™ rapamycin; the outcome of early clinical trials for Palvella's product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella's limited experience in designing clinical trials and lack of experience in conducting clinical trials; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella's current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release. Contact Information Investors Wesley H. Kaupinen Founder and CEO, Palvella Therapeutics Media Marcy Nanus Managing Partner, Trilon Advisors LLC mnanus@ PALVELLA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 5,118 $ 1,442 $ 9,192 $ 2,426 General and administrative 4,132 1,466 7,929 2,241 Total operating expenses 9,250 2,908 17,121 4,667 Loss from operations (9,250 ) (2,908 ) (17,121 ) (4,667 ) Total other income (expense), net (221 ) (1,264 ) (535 ) (2,041 ) Net loss $ (9,471 ) $ (4,172 ) $ (17,656 ) $ (6,708 ) Less: Cumulative Series D preferreddividends — (194 ) — (388 ) Net loss attributable to commonstockholders $ (9,471 ) $ (4,366 ) $ (17,656 ) $ (7,096 ) Net loss per share — basic and diluted $ (0.86 ) $ (2.47 ) $ (1.60 ) $ (4.01 ) Weighted-average number of commonshares used in computing net loss per share— basic and diluted 11,052,741 1,770,167 11,033,327 1,770,167 PALVELLA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION (in thousands) June 30,2025 December 31,2024 Assets Cash and cash equivalents $ 70,433 $ 83,602 Other current assets 3,314 4,632 Total current assets 73,747 88,234 Total assets $ 73,747 $ 88,234 Liabilities and Stockholders' Equity Current liabilities $ 9,616 $ 12,038 Non-current liabilities 16,351 13,589 Total liabilities 25,967 25,627 Total stockholders' equity 47,780 62,607 Total liabilities and stockholders' equity $ 73,747 $ 88,234 Sign in to access your portfolio
